Skip to main content

Table 2 Prognostic value of pathological tumour response for VEGFR-1, VEGFR-2, and TKTL1

From: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

 

VEGFR-1/GUS ≤

Median (n = 13)

VEGFR-1/GUS >

Median (n = 13)

p-value

TRG 2 - 3

9 (69.2%)

8 (61.5%)

p = 1.0

pCR* (ypT0 N0)

2 (15.4%)

1 (7.7%)

p = 1.0

 

VEGFR-2/GUS ≤

Median (n = 16)

VEGFR-2/GUS >

Median (n = 16)

 

TRG 2 - 3

12 (75%)

9 (56%)

p = 0.19

PCR* (ypT0 N0)

2 (16.7%)

1 (6.3%)

p = 1.0

 

TKTL1/GUS ≤

Median (n = 17)

TKTL1/GUS >

Median (n = 16)

 

TRG┼ 2 - 3

11 (64.5%)

11 (68.8%)

p = 1.0

PCR* (ypT0 N0)

1 (5.9%)

2 (12.5%)

p = 0.6

  1. pathological complete remission, Tumour regression grading